Tarenflurbil API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Tarenflurbil API 51543-40-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tarenflurbil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tarenflurbil
- Synonyms:
- (−)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid , (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid , (R)-2-fluoro-α-methyl(1,1'-biphenyl)-4-acetic acid , (R)-flurbiprofen , Tarenflurbil
- Cas Number:
- 51543-40-9
- DrugBank number:
- DB05289
- Unique Ingredient Identifier:
- 501W00OOWA
General Description:
Tarenflurbil, identified by CAS number 51543-40-9, is a notable compound with significant therapeutic applications. Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients. In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in alzheimer's disease and prostate cancer. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Tarenflurbil functions by: MPC-7869 is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). The compound modulates the signal transduction and transcription activation pathways associated with nuclear factor kappaB (NFkappaB), a principle transcription factor in the expression of many molecules involved in cell growth, cell death and inflammation. In addition, MPC-7869 has recently been shown to modulate gamma-secretase and selectively lower levels of Abeta42 peptide in vitro and in vivo, and to reduce amyloid pathology in the brain. MPC-7869 has an excellent safety profile and is very potent in animal models of cancer and Alzheimer's disease. In transgenic mouse studies, MPC-7869 reduced brain amyloid levels and prevented memory loss. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Tarenflurbil belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond, classified under the direct parent group Biphenyls and derivatives. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Biphenyls and derivatives subclass.
Categories:
Tarenflurbil is categorized under the following therapeutic classes: Acids, Acyclic, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antirheumatic Agents, Benzene Derivatives, Biphenyl Compounds, Central Nervous System Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Gamma Secretase Inhibitors and Modulators, Peripheral Nervous System Agents, Propionates, Sensory System Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Tarenflurbil is a type of Analgesics
Analgesics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are commonly used to relieve pain. They are designed to alleviate discomfort by targeting the body's pain receptors or by reducing inflammation. Analgesics are widely utilized in the medical field to manage various types of pain, ranging from mild to severe.
One of the primary classes of analgesics is nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by inhibiting the production of prostaglandins, substances that contribute to pain and inflammation. This class includes well-known drugs like ibuprofen and naproxen. Another class of analgesics is opioids, which are derived from opium or synthetic compounds that mimic the effects of opium. Opioids act on the central nervous system to reduce pain perception and provide potent pain relief. Examples of opioids include morphine, codeine, and oxycodone.
Analgesics are available in various forms, such as tablets, capsules, creams, and injections, allowing for different routes of administration based on the patient's needs. They are commonly used to manage pain associated with conditions like arthritis, headaches, dental procedures, and post-operative recovery.
It is important to note that analgesics should be used under medical supervision, as improper use or overuse can lead to adverse effects, including gastrointestinal complications, addiction, and respiratory depression in the case of opioids. Therefore, it is crucial for healthcare professionals to assess each patient's individual needs and prescribe the appropriate analgesic and dosage.
In summary, analgesics are a vital category of pharmaceutical APIs used to alleviate pain by targeting pain receptors or reducing inflammation. With various classes and forms available, they provide valuable options for pain management when used responsibly and under medical guidance.
